Acesso livre
Acesso livre

Estudo randomizado | Rendesivir não melhora os desfechos em pacientes com COVID-19 admitidos em hospital.

17 Set, 2021 | 12:11h

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial – The Lancet Infectious Diseases

Comentário convidado: Remdesivir, on the road to DisCoVeRy – The Lancet Infectious Diseases

Conteúdos relacionados:

Systematic Review: “Remdesivir probably has little or no effect on all‐cause mortality at up to 28 days in hospitalized adults with SARS‐CoV‐2 infection. We are uncertain about the effects of remdesivir on clinical improvement and worsening”.

WHO Solidarity Trial: Remdesivir, hydroxychloroquine, lopinavir, and interferon regimens had little or no effect on hospitalized patients with Covid-19


Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.